Hepatitis C Facts - Schering-Plough Initiates PEG-INTRON(R) Maintenance Study in Patients Coinfected With Hepatitis C and HIV

Schering-Plough Initiates PEG-INTRON(R) Maintenance Study in Patients Coinfected With Hepatitis C and HIV
[Press Release] PR Newswire via Yahoo! Finance - Jan 12 11:30 PM
Schering-Plough announced today that it is initiating a large multinational clinical trial to evaluate the use of low-dose PEG-INTRON maintenance monotherapy in preventing or delaying hepatitis C disease progression and thus potentially reducing the occurrence of clinical events such as liver transplantation, liver cancer and death in cirrhotic patients with hepatitis C who are coinfected with Save to My Web

Vertex Drug Shows Promise in Hepatitis C
RedNova - Jan 10 3:06 PM
New data from a phase Ib study show that Vertex Pharmaceutical's VX-950 dosed in combination with pegylated interferon alfa-2a, achieved a rapid and dramatic reduction in virus levels in genotype 1 patients with chronic hepatitis C infection.Save to My Web

XTL Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
[Press Release] PR Newswire via Yahoo! Finance - Jan 02 11:48 PM
XTL Biopharmaceuticals, Ltd. , a biopharmaceutical company developing drugs against hepatitis, announced today the appointment of Ron Bentsur as Chief Executive Officer of the Company.Save to My Web